MIZHOU $MRK KEYNOTE-177 PFS Significance in ASCO Late Breaker Has Relevance - BUY, $100 PT-KEYTRUDA reduced risk of disease progression or death by 40% versus standard of care (SOC) (HR=0.60; KEYTRUDA 16.5 months vs. 8.2 months with SOC)
Responses were durable for over 2 years